Ligand Pharmaceuticals LGND Captisol — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's captisol — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's captisol — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported captisol — total revenues and income of $8.65M in Q1 2026.
- How has Ligand Pharmaceuticals's captisol — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's captisol — total revenues and income decreased by 35.7% year-over-year, from $13.46M to $8.65M.
- What is the long-term trend for Ligand Pharmaceuticals's captisol — total revenues and income?
- Over 4 years (2021 to 2025), Ligand Pharmaceuticals's captisol — total revenues and income has grown at a -29.7% compound annual growth rate (CAGR), from $164.25M to $40.21M.
- What does captisol — total revenues and income mean?
- Represents the aggregate financial inflows generated by the Captisol product line, including direct material sales and related service income. This metric serves as a primary indicator of the commercial performance and market adoption of the company's proprietary drug formulation technology.